21-氨基类固醇非糖皮质激素药物Tirilazad mesy-late具有抑制脂质过氧化的作用,可缩小动物局灶性脑缺血的梗死体积。人体研究表明,该药物剂量达到每日每公斤体重6.0mg对健康志愿者卒中病人具有很好的耐受性。作者就Tirilazad治疗起病6h内的急性缺血性卒中进行用药后3个月的疗效评估。 本研究为随机、双盲、赋型剂对照的多中心研究,参加单位来自27个北美中心。病例入选标准为18 21-Aminosteroids Glucocorticoids Tirilazad mesy-late inhibits lipid peroxidation and reduces infarct volume in focal cerebral ischemia in animals. Human studies have shown that the drug dose of 6.0mg per kilogram of body weight per day for healthy volunteers with stroke patients with good tolerance. The authors evaluated the efficacy of 3 months after treatment of acute ischemic stroke within 6 hours of starting Tirilazad treatment. This study was a randomized, double-blind, excipient-based, multicenter study with participants from 27 North American centers. Case selection criteria for 18